Using transgenic plants as bioreactors to produce edible vaccines

Journal of Biotech Research

Volumn 4, Issue 1, 2012, Pages 92-99

  Gunn, Karyn Scissum ^a   Singh, Narendra ^b   Giambrone, Joseph ^b   Wu, Hongzhuan ^a  

^a ALABAMA STATE UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION PROTOCOLS; ANIMAL DISEASE; ARABIDOPSIS THALIANA; AVIAN INFLUENZA; COST EFFECTIVE; EDIBLE VACCINES; ENVIRONMENTAL CONTAMINATION; EXPRESSION LEVELS; HEPATITIS B; IMMUNE TOLERANCES; INFECTIOUS BURSAL DISEASE VIRUS; NORWALK; PLANT SYSTEMS; PROOF OF PRINCIPLES; REOVIRUS; TECHNICAL CHALLENGES; TECHNICAL TRAINING; TRANS-GENES; TRANSGENIC PLANTS; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES; ANTIGENS; BIOCONVERSION; BIOREACTORS; GENETICALLY MODIFIED PLANTS; PERSONNEL TRAINING; RECOMBINANT PROTEINS; TECHNICAL PRESENTATIONS; VACCINES; VIRUSES;

DISEASES;

ANIMALIA; ARABIDOPSIS THALIANA; AVIAN INFLUENZA VIRUS; AVIAN ORTHOREOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS BURSAL DISEASE VIRUS; NOROVIRUS; NORWALK VIRUS;

EID: 84869855268     PISSN: 19443285     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Blueprint for the development of plant-derived vaccines for the poor in developing countries. 2005. Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University.
2. Streatfield SJ. 2006. Mucosal immunization using recombinant plant-based oral vaccines. Methods 38:150-157.
3. Rice J, Ainley WM, Shewen P. 2005. Plant-made vaccines: biotechnology and immunology in animal health. Anim Health Res Rev 6:199-209.
4. Lal P, Ramachandran VG, Goyal R, Sharma R. 2007. Edible vaccines: Current status and future. Indian J Med Microbiol 25:93-102.
5. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L et al. 2000. High-yield production of a human therapeutic protein intobacco chloroplasts. Nat Biotechnol 18:333-338.
6. Tregoning JS, Nixon P, Kuroda H et al. 2003. Expression of tetanus toxin Fragment C in tobacco chloroplasts. Nucl Acids Res 31: 1174-1179.
7. Glenz K, Bouchon B, Stehle T, Wallich R, Simon MM, Warzecha H. 2006. Production of a recombinant bacterial lipoprotein in higher plant chloroplasts. Nat Biotechnol 24:76-77.
8. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. 2000. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18:1167-1171.
9. Haq TA, Mason HS, Clements JD, Arntzen CJ. 1995. Oral Immunization with a Recombinant Bacterial antigen producedin transgenic plants. Science 268:714-716.
10. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. 1996. Proc Natl Acad Sci USA 93:5335-5340.
11. Webster D, Cooney M, Huang Z, Drew DR, Ramshaw IA, Dry IB et al. 2002. Successful boosting of a DNA measles immunisation with an oral plant-derived measles vaccine. J Virol 76: 7910-7912.
12. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, et al. 1999. A plant-derived edible vaccine against hepatitis B virus. FASEB J 13:1796-1799.
13. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. 1998. A plant based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16:934-938.
14. Lauterslager TGM, Florack DEA, van der Wal TJ, Molthof JW, Langeveld JPM, Bosch D, et al. 2001. Oral immunization of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine 19:2749-2755.
15. Wu YZ, Li JT, Mou ZR, Fei L, Ni B, Geng M, et al. 2003. Oral immunization with rotavirusVP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology 313(2):337-342.
16. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. 1998. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 4(5):607-609.
17. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. 2004. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic maize. Vaccine 22:4385-4389.
18. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ, Mason HS. 2005. Immunogenicity inhumans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 102:3378-3382.
19. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. 2000. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182:302-305.
20. Siliciano RF. 2006. Acquired Immune Deficiency Syndrome. In: Encyclopedia of Life Science. Chichester, UK: John Wiley & Sons Ltd, http://www.els.net/[doi:10.1038/npg.els.0003938].
21. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173-178.
22. Haynes BF and Montefiori DC. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 5:579-595.
23. Jiang WZ, Jin NY, Cui SF, Li ZJ, Zhang LS, Zhang HY, Wang HW, Han WY. 2005. Construction and characterization of recombinant fowlpox virus coexpressing HIV-1 gp120 and IL-2. J Virol Methods 130: 95-101.
24. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. 2006. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80: 3122-3125.
25. Janvier B, Archinard P, Mandrand B, Goudeau A, Barin F. 1990. Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2. J Virol. 64(9): 4258-4263.
26. Hogervorst E, Jurrians S, de Wolf F, et al. 1995. Predictor for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy number in serum and maintenance of high HIV-1 p24 specific but not V3-specific antibody levels. J Infect Dis 171: 811-821.
27. Zwart G, Langedijk H, van der Hoek L, de Jong JJ, Wolfs TFW, Ramautarsing C, Bakker M, de Ronde A, Goudsmit J. 1991. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181:481-489.
28. Perez-Filgueira DM, Brayfielda BP, Phiria SMV. 2004. Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV)-derived vector. J Virological Methods 121:201-208.
29. Shchelkunov SN, Salyaev RK, Pozdnyakov SG et al. 2006. Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol Lett 28(13): 959-967.
30. Available from: http://www.sembiosys.com/Products/Diabetes.aspx
31. Lee L-Y, Kononov ME, Bassuner B, Frame BR, Wang K, Gelvin SB. 2007. Novel plant transformation vectors containing the superpromoter. Plant Physi 145:1294-1300.
32. Pascual DW. 2007. Vaccines are for dinner. Proc Natl Acad Sci USA 104:10757-10758.
33. Available from: http://www.plantphys.net/article.php?ch=21andid=216.
34. Available from: http://www.sabin.org/SVR/winter2001_9.htm
35. Haq TA, Mason HS, Clements JD, Arntzen CJ. 1995. Oral Immunization with a Recombinant Bacterial antigen produced in transgenic plants. Science 268:714-716.
36. Wu H, Singh NK, Gunn KS, Giambrone JJ. 2009. Research towards development of an edible vaccine for avian reovirus. Avian Dis 53:376-381.
37. Wu H, Singh NK, Locy RD, Scissum-Gunn K, Giambrone JJ. 2004. Expression of immunogenic VP2 protein of infectious bursal disease virus in Arabidopsis thaliana. Biotechnology letters 26(10):787-792.
38. Wu H, Singh NK, Locy RD, Scissum-Gunn K, Giambrone JJ. 2004. Immunization of chickens with VP2 protein of infectious bursal disease virus expressed in Arabidopsisthaliana. Avian Diseases 48(3):663-668.
39. Yoshimatsu K, Kawano N, Kawahara N, Akiyama H, Teshima R, Nishijima M. 2012. Current status of application and commercialization of genetically modified plants for human and livestock health and phytoremediation. Yakugaku Zasshi 132(5):629-674.